Related Experiment Video
Updated: Sep 14, 2025
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Secondary Malignancies in Patients with Meningioma: A Surveillance, Epidemiology, and End Results Data Analysis
Maxwell W Pickles1, Thomas Z Rohan1, Shreya Vinjamuri1
1Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Background:
The risk of secondary primary malignancies (SPMs) in meningioma patients is not well understood. In this unidirectional analysis, we evaluated the risk of SPMs occurring following a primary diagnosis of meningioma.
Methods:
The Surveillance, Epidemiology, and End Results (SEER-17) database (2000-2020) was used to identify 124,769 meningioma patients from a total of 9,208,295 cancer cases. Standardized incidence ratios (SIRs) were calculated using SEER's statistical analysis package to evaluate SPM risk. Basic demographic and treatment information was collected as well.
Results:
Of the 124,769 patients, 11,411 (9.2%) received diagnoses of an SPM, which correlates to a higher risk than the general population (SIR, 1.17; 99% confidence interval [CI], 1.15-1.19). Patients with meningiomas had an increased risk of the following cancers: cutaneous melanoma (SIR, 1.40; 99% CI, 1.26-1.56), kidney and renal pelvis (SIR, 1.66; 99% CI, 1.47-1.86), brain and other nervous system (SIR, 3.45; 99% CI, 2.99-3.97), thyroid (SIR, 2.48; 99% CI, 2.19-2.80), and non-Hodgkin's lymphoma (SIR, 1.29; 99% CI, 1.15-1.44). Females were more predisposed to cancers of the lung (SIR, 1.19; 99% CI, 1.12-1.26), digestive system (SIR, 1.06; 99% CI, 1.01-1.12), and breast (SIR, 1.09; 99% CI, 1.04-1.14). Older patients demonstrated an increased risk of SPM development, with the 65-85-year-old group having an odds ratio of 9.06 (P = 0.009).
Conclusions:
SEER data confirm an increased risk of SPMs following meningioma diagnosis. Further research may uncover shared genetic factors between meningioma and these SPMs, and increased awareness of SPM risk could inform future screening strategies.
Insights
Meningioma patients face a higher risk of developing secondary primary malignancies (SPMs). This study highlights increased risks for specific cancers, including melanoma and brain tumors, emphasizing the need for heightened awareness and screening strategies.
Area of Science:
- Oncology
- Epidemiology
- Cancer Research
Background:
- The risk of secondary primary malignancies (SPMs) following a meningioma diagnosis is not well-established.
- Meningioma is a primary brain tumor with a significant patient population.
- Understanding SPM risk is crucial for long-term patient management.
Purpose of the Study:
- To evaluate the risk of developing secondary primary malignancies (SPMs) in patients previously diagnosed with meningioma.
- To identify specific cancer types that show an increased incidence after a meningioma diagnosis.
- To analyze demographic factors associated with SPM development in meningioma survivors.
Main Methods:
- Utilized the Surveillance, Epidemiology, and End Results (SEER-17) database from 2000-2020.
- Identified 124,769 patients with a primary meningioma diagnosis.
- Calculated Standardized Incidence Ratios (SIRs) to assess SPM risk compared to the general population.
Main Results:
- A total of 11,411 (9.2%) meningioma patients developed SPMs, indicating a significantly higher risk (SIR, 1.17).
- Elevated SPM risks were observed for cutaneous melanoma, kidney and renal pelvis, brain and other nervous system, thyroid, and non-Hodgkin's lymphoma.
- Females showed increased risks for lung, digestive system, and breast cancers, while older patients (65-85 years) had a substantially higher odds of SPM development.
Conclusions:
- Meningioma diagnosis is associated with an increased risk of secondary primary malignancies.
- Further research into shared genetic factors may elucidate the link between meningioma and SPMs.
- Increased awareness and targeted screening strategies are recommended for meningioma patients to monitor for SPM development.
